Liraglutide enhances glucose transporter 4 translocation via regulation of AMP-activated protein kinase signaling pathways in mouse skeletal muscle cells

Metabolism ◽  
2014 ◽  
Vol 63 (8) ◽  
pp. 1022-1030 ◽  
Author(s):  
Zhu Li ◽  
Chang-Lin Ni ◽  
Zhi Yao ◽  
Li-Ming Chen ◽  
Wen-Yan Niu
2014 ◽  
Vol 2014 ◽  
pp. 1-14 ◽  
Author(s):  
Mei-Hsing Chen ◽  
Cheng-Hsiu Lin ◽  
Chun-Ching Shih

The objective of this study was to evaluate the antihyperlipidemic and antihyperglycemic effects and mechanism of the extract ofClitocybe nuda(CNE), in high-fat- (HF-) fed mice. C57BL/6J was randomly divided into two groups: the control (CON) group was fed with a low-fat diet, whereas the experimental group was fed with a HF diet for 8 weeks. Then, the HF group was subdivided into five groups and was given orally CNE (including C1: 0.2, C2: 0.5, and C3: 1.0 g/kg/day extracts) or rosiglitazone (Rosi) or vehicle for 4 weeks. CNE effectively prevented HF-diet-induced increases in the levels of blood glucose, triglyceride, insulin (P<0.001,P<0.01,P<0.05, resp.) and attenuated insulin resistance. By treatment with CNE, body weight gain, weights of white adipose tissue (WAT) and hepatic triacylglycerol content were reduced; moreover, adipocytes in the visceral depots showed a reduction in size. By treatment with CNE, the protein contents of glucose transporter 4 (GLUT4) were significantly increased in C3-treated group in the skeletal muscle. Furthermore, CNE reduces the hepatic expression of glucose-6-phosphatase (G6Pase) and glucose production. CNE significantly increases protein contents of phospho-AMP-activated protein kinase (AMPK) in the skeletal muscle and adipose and liver tissues. Therefore, it is possible that the activation of AMPK by CNE leads to diminished gluconeogenesis in the liver and enhanced glucose uptake in skeletal muscle. It is shown that CNE exhibits hypolipidemic effect in HF-fed mice by increasing ATGL expression, which is known to help triglyceride to hydrolyze. Moreover, antidiabetic properties of CNE occurred as a result of decreased hepatic glucose production via G6Pase downregulation and improved insulin sensitization. Thus, amelioration of diabetic and dyslipidemic states by CNE in HF-fed mice occurred by regulation of GLUT4, G6Pase, ATGL, and AMPK phosphorylation.


PLoS ONE ◽  
2008 ◽  
Vol 3 (10) ◽  
pp. e3614 ◽  
Author(s):  
Isabella Irrcher ◽  
Vladimir Ljubicic ◽  
Angie F. Kirwan ◽  
David A. Hood

Author(s):  
Abraham Giacoman-Martínez ◽  
Francisco Javier Alarcón-Aguilar ◽  
Alejandro Zamilpa-Alvarez ◽  
Fengyang Huang ◽  
Rodrigo Romero ◽  
...  

α-amyrin, a natural pentacyclic triterpene, have anti-hyperglycemic effect in mice and dual PPARδ/γ action in 3T3-L1 adipocytes, and potential in the control of type 2 diabetes (T2D). About 80% of glucose uptake occurs in skeletal muscle cells, playing a significant role in IR and T2D. Peroxisome-proliferator activated receptors (PPARs), in particular PPARδ and PPARγ, are involved in the regulation of lipids and carbohydrates and, along adenosine-monophosphate (AMP)-activated protein kinase (AMPK) and protein kinase B (Akt/PKB), are implicated in translocation of glucose transporter 4 (GLUT4). However, it is still unknown whether α-amyrin can affect these pathways in skeletal muscle cells. The work's objective was to determine the action of α-amyrin in PPARδ, PPARγ, AMPK, and Akt/PKB in C2C12 myoblasts. The expression of PPARδ, PPARγ, FATP, and GLUT4 was quantified using RT-qPCR and Western blot. α-amyrin increased these markers along with p-AMPK but not p-Akt/PKB. Molecular docking showed that α-amyrin acts as an AMPK-allosteric activator, and may be related to GLUT4 translocation, evidenced by confocal microscopy. These data support that α-amyrin could have an insulin-mimetic action in C2C12 myoblasts and should be considered as a bioactive molecule for new multitarget drugs with utility in T2D and other metabolic diseases.


Sign in / Sign up

Export Citation Format

Share Document